Toxic Epidermal Necrolysis and Epidermolysis Bullosa successfully treated with cultured skin grafts EPIFAST

Massé Sánchez A., Hernández Aguilar G., Mexican Social Security Institute, Pediatric Plastic Surgery, México

INTRODUCTION.- Toxic Epidermal Necrolysis (TEN) Most of the cases are drug-induced. Immunological reactions are implicated (keratinocytes apoptosis). **Epidermolysis bullosa (EB)** is a disease of the skin transmitted genetically is classified (genodermatosis).

OBJETIVE.- To seek an appropriate treatment for patients with **Toxic Epidermal Necrolysis (TEN)** and **Epidermolysis bullosa (EB)** since there are no guidelines for it, and the patients behave as burned ones. Therefore, **cultured skin grafts “EPIFAST”** were used.

METHODOLOGY.-1,2- A 3 and 11 years old female developed an adverse reaction to medication, after 48 hrs, a **Toxic Epidermal Necrolysis (TEN)** was developed in 80% of the body surface (skin). 3.- 6 years of old male with Convulsive crisis, which makes allergy to Lamotrigina at 7 days, **TEN was developed** in 75% of the body surface, meriting intensive care management.

4, 5.- Female 3 and 12 years old with Epidermolysis Bullosa on different parts of the body and infection.

RESULTS.- On the 1st day of treatment, Epifast was applied to 5 patients (50% of the lesions to patients with NET and 100% to NB) were removed one week later, and Epifast was applied in the other 50% of the lesion (NET), the patient with EB healed with a single application of Epifast.

DISSCUSSION.- There are no previous **Toxic Epidermal Necrolysis or Epidermolysis bullosa** treatments reported in medical literature following these procedures, **cultured skin grafts EPIFAST** showed to be an ideal proved-treatment for **these cases**; obtaining a good quality epithelium within 5 days after application.

CONCLUSIONS: The surgical technique applied with **cultured skin grafts EPIFAST**, demonstrated better results than expected, since adequate skin cover throughout the treated surface was achieved. It stimulates the healing and shortened the recovery period of the patient.

Epidermolysis Bullosa

1th week epifast (full of epithelization)

3th week epifast weekly

4th Months epifast weekly application, outpatient

Toxic Epidermal Necrolysis

1 and 3 weeks after Epifast

1. Aviakian R., Flowers FP., Araujo OE., Ramos-Caro FA.: "Toxic epidermal necrolysis: a review" J. Am. Acad. Dermatol. 1991; 25: 69. 2. Roujeau JC., Stern RS.: "Severe adverse cutaneous reactions to drugs". New Engl. J. Med. 1994; 331: 1272. 3. Cros A. et al.: "Sindrome de Stevens Johnson". Rev. Med. Uruguay 2004; 20 (3): 172. 4. Roujeau JC., Kelly JP., Naldi L. et al.: "Medication use and the risk of Stevens Johnson Syndrome or toxic epidermal necrolysis". New Engl. J. Med. 1995; 333 (24): 1600. 5. Gómez de la Garza M.: "Necrolisis Epidérmica Tóxica" Dermatología Rev. Mex. 1994; 38 (supl. 4): 417. 6. Roujeau JC., Chesinow C., Saiag P., Guillaume JC.: "Toxic epidermal necrolysis (Lyell Syndrome)". J. Am. Acad. Dermatol. 1990; 23: 1039. 7. Pacheco L., Sánchez MA., Sánchez DL.: "Síndrome de Stevens Johnson. Presentación de un caso". Rev. Cubana Pediatr. 2001; 73 (4): 240. 8. Ringheanu M. et al.: "Toxic epidermal necrolysis in children: an update". Clin. Pediatr. 2000; 39 (12): 687. 9. Roujeau JC., Stern RS. et al.: "Toxic epidermal necrolysis: clinical and pathogenetic considerations. Br J Dermatol 1995; 132: 339-44. 2. Hovnanian A, Christiano AM, Vitto J. The molecular genetics of dystrophic epidermolysis bullosa. Arch Dermatol 1993; 129: 1568-9. 3. Bergman B. Immunohistopathologic diagnosis of epidermolysis bullosa. Am J of Dermatopathol 1999; 21: 185-92. 4. Epstein EH Jr. Molecular genetics of epidermolysis bullosa. Science 1992; 256: 799-804. 5. Smith LT. Ultrastructural findings in epidermolysis bullosa. Arch Dermatol 1993; 129: 1578-84